Recommendations for donation after circulatory death kidney transplantation in Europe. by van Heurn, L. W. Ernest et al.
REVIEW
Recommendations for donation after circulatory death
kidney transplantation in Europe
L. W. Ernest van Heurn,1 David Talbot,2 Michael L. Nicholson,3 Mohammed Z. Akhtar,4
Ana I. Sanchez-Fructuoso,5 Laurent Weekers6 and Benoit Barrou7
1 Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands
2 Department of Liver/Renal Transplant, Freeman Hospital, Newcastle Upon Tyne, UK
3 Department of Surgery, NIHR Cambridge Biomedical Research Centre, Cambridge, UK
4 Oxford Transplant Centre, University of Oxford, Oxford, UK
5 Department of Nephrology, Hospital Clınico Universitario San Carlos, Madrid, Spain
6 Department of Nephrology-Dialysis-Transplantation, University of Liege, CHU Sart Tilman, Liege, Belgium
7 Department of Urology - Transplantation, GHzu Pitie Salpe^triere, Paris, France
Keywords
donation after cardiac death, donation after
circulatory death, guidelines, kidney, nonheart
beating donation, review.
Correspondence
L. W. Ernest van Heurn, Department of
Surgery, Academic Medical Centre ,
Amsterdam, The Netherlands P.O. Box 22660
1100 DD Amsterdam
Tel.: +31 20 5665693;
fax: +31 20 5669287;
e-mail: e.vanheurn@amc.nl
Conflicts of interest
The authors declare no conflict of interest.
Received: 13 May 2015
Revision requested: 19 June 2015
Accepted: 26 August 2015
doi:10.1111/tri.12682
Summary
Donation after circulatory death (DCD) donors provides an invaluable source for
kidneys for transplantation. Over the last decade, we have observed a substantial
increase in the number of DCD kidneys, particularly within Europe. We provide
an overview of risk factors associated with DCD kidney function and survival and
formulate recommendations from the sixth international conference on organ
donation in Paris, for best-practice guidelines. A systematic review of the litera-
ture was performed using Ovid Medline, Embase and Cochrane databases. Topics
are discussed, including donor selection, organ procurement, organ preservation,
recipient selection and transplant management.
Introduction
Donation after circulatory death (DCD) has shown to pro-
vide a valuable expansion of the number of donor organs
available for transplantation. In some countries such as the
Netherlands and the United Kingdom, DCD transplanta-
tion has almost doubled the number of deceased organ
donors (NHSBT data 2014). However, DCD organs sustain
an inevitable period of warm ischemia after circulatory
arrest, which may have serious implications for early and
late graft function after transplantation. There are many
comparative studies between DCD kidney transplantation
and transplantation of kidneys from donors after brain
death (DBD) with, depending on the number of included
patients and the selection of DCD donors, variable results
[1–3]. The general opinion is that DCD transplantation is
associated with a higher risk of primary nonfunction (PNF)
and delayed graft function (DGF). The higher incidence of
DGF after DCD transplantation, however, is not associated
with graft survival as in DBD grafts [4,5].
Despite the higher incidence of PNF and DGF after DCD
transplantation, little is known about the specific risk fac-
tors for kidney function after transplantation and selection
of DCD grafts. Very strict organ selection may reduce the
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risk of poor initial function after transplantation, but it also
carries the risk that viable organs are discarded, which may
result in the death of patients on the waiting list who other-
wise could have been transplanted [6].
To extend the number of DCD kidneys, more knowledge
about risk factors associated with poor kidney function and
graft survival is required. Most risk factors for the outcome
of kidney transplantation have been identified in DBD
only, or in cohorts, which include both DBD and DCD
grafts [7,8] It is inappropriate to extrapolate the results of
DBD kidney viability studies to DCD kidneys because of
the influence of the prior warm ischemia. Therefore, we
looked for specific risk factors for DCD kidney function
and graft survival after transplantation, graded the level of
evidence of the available literature and formulated recom-
mendations of best-practice guidelines, when possible.
The guidelines are divided into sections including on
donor selection, ischemia times, kidney procurement, kid-
ney preservation and recipient selection. A number of
issues surrounding the management of patients, including
paediatric kidney transplantation, are discussed. A recom-
mendation table is provided as a summary at the end with
the corresponding level of evidence.
Methods
Potentially relevant studies were identified with a struc-
tured computerised search of the English literature of Ovid
Medline, Embase and Cochrane databases. Keywords
included ‘donation after cardiac death’, ‘donation after
circulatory death’, ‘nonheart beating donor’, ‘kidney
transplantation’ ‘viability’, ‘extracorporeal membrane oxy-
genation’, ‘cold storage’, ‘hypothermic machine perfusion
(HMP)’, ‘hypertension’, ‘diabetes’, ‘obesity’, ‘organ preser-
vation’, ‘tissue and organ procurement’ ‘transplantation’,
‘warm ischemia time’ and ‘outcome’ combined with free
text searching. The level of scientific evidence of the rele-
vant studies was assessed, and accordingly, recommenda-
tions were made and graded by an expert panel. These
recommendations were presented at 6th International Con-
ference on Organ Donation after Circulatory Death in Paris
of the European Society of Organ Transplantation, where
the concept recommendations were presented, discussed
with the various expert panels and congress participants.
Donor selection
Age
In comparative studies including data from national and
large centre databases with multivariate risk analyses for
DCD kidney transplantation, donor age is an independent
risk factor for PNF, DGF, creatinine clearance 1 year after
transplantation and graft survival [9,10–18]. The hazard
ratio for graft failure is higher and may be more than dou-
bled for DCD kidney transplantation from donors aged 60
or older compared with donors aged 40 years or younger
[10,12,14,19].
Paediatric DCD kidney transplantation is rarely done
[20]. In general, paediatric donor kidneys are at increased
risk for graft thrombosis due to low flow and relatively small
vessels [21,22]. This risk is aggravated by warm ischemic
damage with an inflammatory response and oedema of the
kidney [23]. In a relatively large comparative study of paedi-
atric DBD and DCD kidneys, DCD kidneys had a higher
risk of both PNF (OR: 5.3) and DGF and were associated
with a higher risk of graft failure with a hazard ratio of 2.5.
In the same group, also kidneys from donors younger than
10 years of age had an increased risk of graft failure [24].
Donor BMI, hypertension, diabetes, serum creatinine, and
cause of death
High donor BMI as a risk factor for DGF and graft failure
was found to have a hazard ratio of up to 1.84 for DCD
kidneys from donors with BMI > 45 kg/m² [12,16,25,26].
Hypertension, diabetes, high donor creatinine and donor
cause of death are DCD donor variables which affect trans-
plant outcome in large retrospective cohort studies. Donor
hypertension, diabetes, high donor creatinine and death
from cerebro-vascular accident may increase the risk of
DGF and graft loss [12,16,26,27]. These findings are largely
influenced by the large UNOS database and are generally
consistent with the findings in other, smaller, cohorts of
DCD transplants, which fail to reach statistical significance.
The reported additional risk of graft loss is usually relatively
limited. However, data may be biased by donor selection
prior to transplantation and exact measurements are usu-
ally not present.
Pre-implantation renal biopsy
In kidneys from DBD donors, pre-implantation histology is
a predictor of outcome and can improve transplant out-
come if those kidneys are not transplanted that are identi-
fied as probable failures [28–30]. In DCD kidneys, two
groups showed that baseline donor kidney disease assessed
with histology scores influenced graft survival and that pre-
implantation histology assessment might improve the selec-
tion of old donors after cardiac death [31,32]. Histological
assessment of pretransplant kidneys with small needle biop-
sies is reproducible and representative [33].
Ischaemia time
Agonal time
Agonal time, defined as the period of time between with-
drawal of life support and circulatory arrest, is in most
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protocols limited to 2 h to maximize the period of rela-
tively poor tissue oxygenation due to respiratory failure
and decreasing tissue perfusion after life support has been
withdrawn. It has been shown to be possible to extend this
period to longer than 4 h without adverse effects with an
equivalent renal function of DCD kidneys procured after a
prolonged agonal time and kidneys with a shorter agonal
time [34,35].
Warm ischaemia time
A period of warm ischemia, the time between circulatory
arrest to the start of organ perfusion, had, in a series of
2562 DCD kidneys in the UNOS database, no detrimental
effect on transplant outcome other than a higher incidence
of DGF, if this period was limited to 30 min [16]. This
finding was confirmed by an analysis of 845 Maastricht III
DCD kidneys transplanted in the UK. A subgroup of 173
kidneys with a primary warm ischaemia time greater than
20 min had no increased graft failure rates in comparison
with kidneys with shorter ischaemia times.
Others showed that a warm ischaemia period of greater
than 40 min was an independent risk factor for kidney fail-
ure and was particularly significant if present with another
risk factor such as cold ischemic time above 18 h or donor
age greater than 55 years [36].
Cold ischaemia time
Cold ischaemia has a negative impact on transplant out-
come. Evidence from animal experiments suggests that
organs derived from DCDs are more sensitive to cold
ischaemia than those from DBDs [37,38]. Large clinical ser-
ies show that a long period of cold ischaemia in DCD kid-
neys is associated with a higher incidence of PNF, DGF and
poor graft survival [10,16,39]. Individual centres reviewing
paired kidneys found that the second of a pair of DCD kid-
neys with longer cold ischaemia had a higher incidence of
DGF [40]. The limits of acceptable cold ischaemia time are
not known, but the negative influence of cold ischaemia on
transplant outcome is likely to be additional to the other
donor risk factors, for example donor age or prolonged
warm ischaemia.
Procurement of DCD kidneys
Warm ischemic damage in DCD can be reduced by
lowering the temperature as quickly as possible or by per-
fusing the organs at body temperature to partly correct
warm ischaemic injury, before the organs are cooled down
[41–43].
Three perfusion techniques are commonly used to pre-
serve kidneys before procurement including rapid laparo-
tomy with direct aorta cannulation, in situ perfusion (ISP),
and extracorporeal regional perfusion (RP).
Rapid laparotomy and direct aorta cannulation can only
be performed in Maastricht category III donors, if consent
for donation is obtained before withdrawal of life support.
It allows introduction of large cannulas enabling high flow
cold perfusion [44]. As a laparotomy is done, topical cool-
ing (TC) of the organs can be performed.
In situ perfusion with insertion of the cannulas into the
femoral vessels can be used in both Maastricht category I or
II (uncontrolled) donors and in controlled donors, often
before consent for donation has been obtained [44]. The
cannula with a double balloon and a triple lumen has a rel-
atively small diameter providing a lower flow than cannulas
used for direct aorta cannulation [45].
Regional perfusion uses extracorporeal machine oxy-
genation circuit to selectively perfuse the abdominal organs
after cannulation of the femoral vessels. This technique has
been originally used to cool organs down in DBD donors
and later in uncontrolled DCD donors [hypothermic regio-
nal perfusion (HRP)] [46–48]. In a second phase, it has
been used to reperfuse the organs at body temperature
(normothermic RP, NRP). The concept relies on experi-
mental studies, mostly performed in liver or kidney trans-
plantation models in pigs [41–43,49].
The choice for which method is preferable depends on
the Maastricht category (controlled versus uncontrolled)
and the environment.
Kidney procurement in Maastricht category I and II
donors
In uncontrolled donors, both ISP and NR can be used to
procure kidneys. There is some evidence that NRP may
beneficial to restore energy status; however, the number of
clinical studies is small [41,47,49]. Small retrospective clini-
cal studies show excellent results of HRP and NRP to pro-
cure uncontrolled DCD kidneys [50–54,55]. NRP in eight
kidneys has a lower incidence of PNF and DGF than kid-
neys preserved with ISP (44 kidneys) or total body cooling
by extracorporeal support at 4 °C (eight kidneys) [50]. In
another comparative study in 53 patients, kidneys after
NRP had earlier diuresis and better creatinine clearance
1 month after transplantation [54].
Kidney procurement in Maastricht category III donors
In a single centre retrospective study of Maastricht category
III donors, direct aortic cannulation resulted in a shorter
warm ischemia time and a lower discard rate than ISP [44].
The findings were confirmed after adding a second cohort
from another centre: direct aorta cannulation in 63 donors
was associated with a lower discard rate (4.8 vs. 28.2%),
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shorter warm (22 vs. 27 min) and cold (19 vs. 24 h) ischae-
mia time and improved graft survival (86.2% vs. 76.8% at
1 year) compared with ISP (102 donors) [56]. Others
reported PNF in three grafts after technical difficulties
inserting the cannulas using ISP [57].
Hypothermic regional perfusion and NRP are also used
in controlled donors with good results [58–65]. In a com-
parative study, HRP at 22 °C (19 kidneys) was associated
with less DGF (21% vs. 55%) and a lower estimated
glomerular filtration rate (e-GFR) at 1 month than direct
aorta cannulation; however, after 1 year, the eGFR was
equivalent [59,60]. NRP in 24 kidneys showed comparable
results as a historical group of 100 DBD kidneys [64,65].
The costs and complexity of NRP are relatively high. As
there is no high level evidence that NRP in controlled DCD
is superior to direct aorta cannulation, it is questionable
whether the potential benefits outweigh the costs and risks.
In addition, NRP done badly (eg blocked lines) produces
irreversible damage to the organ.
Peritoneal cooling
Topical cooling is used to obtain a faster and deeper cool-
ing of the organs before and during procurement. It has
been used in donors with ISP before laparotomy using two
catheters to flush and drain the peritoneal cavity [66]. In an
animal study, the renal temperature was significantly lower
with TC in addition to normal cold intravascular flush
[67]. Immersing the cooling coil in subzero fluids gave a
faster decrease in the intraperitoneal temperature with
reduction in DGF [68]. The disadvantage is that it adds
more technical procedures to be done in ICU, and it is
more difficult to present to the patient’s family.
Streptokinase in kidney procurement
In rats, the addition of streptokinase to a warm preflush
was associated with an improvement of functional capillary
density of the kidney and reduced early manifestation of
tubular necrosis [69]. In pigs, the addition of streptokinase
(1.5 MIU/l) gave better cooling, machine perfusion charac-
teristics and histology scores [70]. In a randomized con-
trolled study in humans, machine preserved DCD kidneys
from streptokinase-treated donors showed superior
machine preservation characteristics with lower perfusate
biomarker concentrations as indicators for kidney injury
[71].
Preservation of DCD kidneys
HMP versus cold storage
The two different approaches currently in use for the
preservation of transplant kidneys are static cold storage
(CS) and HMP. In CS, the kidneys are stored in melting
ice; in HMP, the kidneys are preserved recirculating cold
preservation solution.
Level 1 evidence comparing HMP with CS includes one
meta-analysis of published articles between 1971 and 2001,
including both DBD and DCD kidneys [72]. The meta-
analysis suggested that HMP was associated with a relative
risk of DGF of 0.804 [0.672–0.961] and that the reduction
in DGF associated with HMP predicted a modest improve-
ment in 10-year graft survival of 3%. However, the quality
of the analysed studies was generally poor.
In DCD transplantation, four randomized controlled tri-
als (RCTs) containing a total of 351 kidneys compared CS
and HMP [18,73–75]. Although the majority of the avail-
able evidence is in favour of HMP, reducing the incidence
of DGF, the recent RCT evidence failed to reach uniform
conclusions. The best evidence from two recent RCTs is
contradictory [18,75]. In a European trial which perfused
kidneys immediately after explantation, HMP reduced the
incidence of DGF; in a randomized study in the United
Kingdom, kidneys were machine perfused at a later stage,
and in this study, there was no difference between CS and
HMP. Therefore, the question of whether or not HMP
reduces the incidence of DGF should be considered unan-
swered.
Machine preservation intrarenal resistance
Machine preservation characteristics are commonly used
for graft selection of DBD and DCD kidneys; however, the
level of evidence of the benefits of this selection is usually
poor. Results are often biased, as kidneys with high intrare-
nal resistance are not transplanted [76–81]. Two studies, in
which kidneys were transplanted irrespective of intrarenal
resistance, one including both DBD and DCD kidneys and
the other DCD kidneys only, showed that intrarenal resis-
tance was an independent risk factor for PNF, DGF and
1-year graft survival [82,83]. The predictive value of intrar-
enal resistance was poor to moderate, so that it cannot be
used as a stand-alone quality tool to predict outcome with
sufficient precision.
Machine perfusate biomarker concentration
The value of machine perfusate biomarker concentration as
predictor for kidney allograft outcome has been studied
extensively [84,85]. Most studies are of relatively poor qual-
ity or include only DBD kidneys [86–88]. The number of
acceptable or good-quality studies including DCD kidneys
is limited [85–92]. From these studies, it can be concluded
that the predictive value of the currently used perfusate bio-
marker concentrations is too low to justify to discard other-
wise good donor kidneys.
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Recipient selection for DCD kidneys
A meta-analysis in 2005 shows that DCD kidney transplan-
tation carries a 3.6 fold increase in the risk of DGF com-
pared with DBD kidneys, which is confirmed by more
recent comparative studies [10,16,39,93–99]. There have
been no specific recipients characteristics identified that are
associated with DGF in DCD transplantation although
there was a trend for more DGF in male recipients and
patients with prolonged dialysis [39]. The effect of recipient
age on graft function and graft survival remains unclear
[16,18,59].
Delayed graft function is generally considered to impact
long-term graft survival, but almost every study evaluating
the consequences of DGF in DCD shows that DGF has not
the same adverse affect on graft survival as in DBD. An
exception is a study of U.S. Renal Data System database
including 708 DCD kidneys where DGF was an indepen-
dent predictor of graft loss in a multivariate analysis [16].
The incidence of PNF is also higher in DCD kidneys than
in DBD kidneys [6,16,96]. There have been no recipient
characteristics identified affecting this outcome.
Death censored graft survival of DCD kidneys depends
on the selection of DCD kidneys and is in most studies
slightly higher to equivalent to DBD kidneys. Particularly
in children and in re-transplantation, DCD kidneys were at
higher risk for graft failure [10,16,99].
Paediatric recipients
Theoretically, DCD kidneys need a higher arterial blood
pressure to get an adequate perfusion pressure, as DCD
kidney transplantation is associated with an inflammatory
reaction and oedema. There is evidence that DCD kidney
transplantation in children is associated with a higher rate
of DGF and reduced graft survival rate than paediatric
DBD kidneys with a more than doubled hazard ratio [99].
When allocating a DCD kidney to a child, it is necessary to
weigh the slightly higher risk of graft failure by accepting a
DCD kidney against the risks associated with staying on the
waiting list for a longer period.
Retransplantation
Repeated transplantation is a known risk factor for worse
outcome after kidney transplantation. Two studies tested
the consequence of repeated transplantation for PNF with
inconsistent results. The Maastricht team reported no effect
of retransplantation on the incidence of PNF in a selected
group, in which DCD kidneys were preferably not allocated
for retransplantation, and the UK database shows that the
incidence of PNF was more than doubled after DCD
retransplantation (3% vs. 7% in first and second graft
recipients, respectively [10,98]). This and the U.S. Renal
Data System show a lower graft survival after DCD retrans-
plantation with a hazard ratios of 2.74 [1.96–3.82] and 4.59
[2.19–9.64] for second and third transplants, respectively,
in the latter study [10,16]. It is unknown whether retrans-
plantation with DCD kidneys provides survival advantage
as compared to remaining longer on the waiting list for a
DBD kidney.
DCD kidney transplant management
The incidence of PNF and DGF is increased in DCD kidney
transplantation. Few studies discuss protocols for improv-
ing the outcome of DCD transplant procedures [100–104].
Fluid management
Fluid depletion in kidney transplantation is associated
with decreased initial graft function [105,106]. In DBD
kidneys, pre-operative and operative fluid loading
reduced the DGF rate [107–110]. In a retrospective study
in recipients of DCD kidneys, low intra-operative central
venous pressure and low blood pressure in recipients
from DCD increased the risk of PNF [103]. It may be
beneficial to keep the recipient well hydrated, avoid
immediate post-transplant dialysis with a negative bal-
ance and monitor venous pressure during and immedi-
ately after the surgical procedure.
Post-transplant monitoring
Patients with a nonfunctioning graft should be monitored
regularly with echo Doppler, renography or both to rule
out other causes than acute tubular necrosis for, usually
temporary, inadequate function of the transplanted kidney.
Moreover, it is difficult to diagnose rejection in patients
with a nonfunctioning graft. Therefore, biopsies should be
taken frequently. Many centres take weekly biopsies until
kidney function improves.
Immunosuppressive therapy protocol
Donation after circulatory death kidneys are susceptible
to calcineurin inhibitor (CNI)-mediated vasoconstriction
and nephrotoxicity. Prompt use of CNI may exacerbate
ischemic injury, delay recovery from DGF and impair
long-term graft function. It is possible to avoid or post-
pone the use of CNI’s or use low doses. Polyclonal anti-
bodies or imTOR inhibitors may be used to postpone or
avoid the use of CNI’s in DCD kidney recipients. In
addition, antithymocyte globulins (ATG) seem to protect
against the damage caused by ischemia–reperfusion
[111].
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There are few published clinical data on immunosup-
pression in DCD kidney recipients. In the 1990s, treatment
with ATG and initiation of cyclosporine 2 days before the
withdrawal of ATG was associated with a low incidence of
rejection, but increased risk of opportunistic infections,
which decreased patient and graft survival [102]. Results
were improved by the use of anti-IL-2R antibodies com-
bined with low doses of tacrolimus and mycophenolate
mofetil [101]. In a randomized trial, induction with dacli-
zumab and delayed introduction of tacrolimus reduced the
incidence of DGF in DCD kidney recipients [104].




Transplantation of old aged donor kidneys
to recipients with a long life expectancy
(e.g. young recipients) should be avoided
B [10,12,14,19]
DCD kidneys from young children should
be used with caution
C [24]
Donor BMI, hypertension, diabetes and
death from cerebro-vascular accident
should be considered in allocation DCD
kidneys
C [12,16,25–27]
Pretransplant renal biopsy is helpful for
selection and thereby improves graft
survival of DCD kidneys from donors
aged 60 years or older
D [28,30–33]
Ischemia times
An agonal time of 2 h or longer is not an
absolute contra-indication for kidney
donation
B [34,35]
The warm ischaemia time in DCD donors
should be maintained as short as
possible. In category III donors, a limited
period of warm ischemia (up to
20–30 min) increases the DGF rate but
has no or only minimal detrimental effect
on graft survival, and is not a contra-
indication for transplantation. DCD
kidneys with a longer warm ischemia
time than 40 min should be used with
caution, particularly if there are more risk
factors for primary nonfunction
C [16,36]
Every effort should be made to minimize
cold ischaemia time and to transplant




The best method to perfuse uncontrolled
DCD kidneys is normothermic
(or subnormothermic) extracorporeal
support with oxygenation. However, if
done badly, normothermic perfusion is
very destructive and cold perfusion
scenario is more forgiving
C [41,47,49–52,
54,55]
A skin incision and dissection of the
femoral vessels may facilitate the
installation of femoral catheters if the
donor receives cardiac massage
D [44]
Rapid laparotomy and direct cannulation
of the aorta is the preferred technique in
Maastricht category III donors if
logistically feasible. In situ preservation
with a double balloon triple lumen
catheter can be used safely to preserve
kidneys in Maastricht category III donors,





In donors with in situ preservation (ISP),
intraperitoneal cooling may allow a
better cooling of the organs than ISP
alone
D [66–68]
It is recommended to use streptokinase




Hypothermic machine perfusion is feasible
and safe. In DCD kidneys, HMP has not
shown an effect on graft survival
B [18,72–75]
If HMP is used to preserve DCD kidneys, it
may be preferable to use it immediately
after kidney explantation
D [18]
Discard of DCD kidneys on the basis of
machine perfusion characteristics or




The risk of DGF should not be considered
as a criterion to discard a DCD kidney for
transplantation
B [10,16,39,93–99]
Children should preferably not receive a
DCD kidney
C [99]
DCD kidneys are not the first choice for
patients with a retransplantation
C [10,16,98]
Recipient management
DCD kidney transplantation should be
avoided in patients with known cardiac
failure or low blood pressure
D
Optimal pre-operative, operative and
direct postoperative fluid management is
essential to optimize graft survival of
DCD kidneys
C [103,105,106]
In DCD kidney recipients with DGF,
regular monitoring with echo Doppler,
renography, or both is recommended, as
well as frequent biopsies, in order to rule
out acute rejection
D
Delayed implementation or use of low-
dose CNI could help to reduce the
incidence of DGF
D [104]
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Conclusion
Donation after circulatory death kidney transplantation has
occurred as consequence of the need to address the organ
deficit. These guidelines provide recommendations on
donor selection, organ and recipient management. The
paucity of high-quality evidence (grade A or above) high-
lights the need for ongoing research into how to optimize
and risk stratify DCD kidneys for transplantation. The
development of new techniques for organ procurement,
ex-situ preservation and recipient management will result
in improvements in outcomes. A summary of recommen-
dations for clinical guidelines are provided in Table 1.
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